A Decade of Advances in Treatment for Advanced Non-Small Cell Lung Cancer

被引:62
作者
Gettinger, Scott [1 ]
Lynch, Thomas [2 ]
机构
[1] Yale Univ, Sch Med, Div Med Oncol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Div Med Oncol, Yale Canc Ctr,Smilow Canc Hosp, New Haven, CT 06520 USA
关键词
Lung cancer; Personalized; Targeted; Epidermal growth factor receptor; ERCC1; Anaplastic lymphoma kinase; MESSENGER-RNA EXPRESSION; PREVIOUSLY TREATED PATIENTS; FACTOR RECEPTOR MUTATIONS; PHASE-III TRIAL; ACQUIRED-RESISTANCE; ADENOCARCINOMA PATIENTS; TYROSINE KINASE; EGFR MUTATIONS; GENE-MUTATIONS; OVARIAN-CANCER;
D O I
10.1016/j.ccm.2011.08.017
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The last decade has heralded a paradigm shift in the evaluation and treatment of advanced non-small cell lung cancer (NSCLC). No longer are patients with NSCLC considered a homogeneous population treated in the same way; rather, clinical characteristics, histology, and an expanding array of molecular markers are increasingly being used to individualize therapy. Both histology and tumor epidermal growth factor receptor mutational status currently have firmly established roles in determining initial and salvage therapy for advanced NSCLC. Several other biomarkers are the focus of ongoing prospective randomized clinical trials customizing both traditional chemotherapy and newer molecularly targeted agents.
引用
收藏
页码:839 / +
页数:14
相关论文
共 83 条
[1]  
[Anonymous], 35 EUR SOC MED ONC C
[2]  
[Anonymous], EARLY RELEASE SELECT
[3]  
[Anonymous], 2010, CANCER
[4]  
[Anonymous], J THORAC ONCOL P
[5]  
[Anonymous], MOL PROFILING LUNG C
[6]  
[Anonymous], 35 EUR SOC MED ONC C
[7]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[8]   The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions [J].
Antoniou, A. C. ;
Cunningham, A. P. ;
Peto, J. ;
Evans, D. G. ;
Lalloo, F. ;
Narod, S. A. ;
Risch, H. A. ;
Eyfjord, J. E. ;
Hopper, J. L. ;
Southey, M. C. ;
Olsson, H. ;
Johannsson, O. ;
Borg, A. ;
Passini, B. ;
Radice, P. ;
Manoukian, S. ;
Eccles, D. M. ;
Tang, N. ;
Olah, E. ;
Anton-Culver, H. ;
Warner, E. ;
Lubinski, J. ;
Gronwald, J. ;
Gorski, B. ;
Tryggvadottir, L. ;
Syrjakoski, K. ;
Kallioniemi, O-P ;
Eerola, H. ;
Nevanlinna, H. ;
Pharoah, P. D. P. ;
Easton, D. F. .
BRITISH JOURNAL OF CANCER, 2008, 98 (08) :1457-1466
[9]   Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay [J].
Arcila, Maria E. ;
Oxnard, Geoffrey R. ;
Nafa, Khedoudja ;
Riely, Gregory J. ;
Solomon, Stephen B. ;
Zakowski, Maureen F. ;
Kris, Mark G. ;
Pao, William ;
Miller, Vincent A. ;
Ladanyi, Marc .
CLINICAL CANCER RESEARCH, 2011, 17 (05) :1169-1180
[10]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937